Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Applications of bacteriophages versus phage enzymes to combat and cure bacterial infections: an ambitious and also a realistic application?

Maciejewska B, Olszak T, Drulis-Kawa Z.

Appl Microbiol Biotechnol. 2018 Mar;102(6):2563-2581. doi: 10.1007/s00253-018-8811-1. Epub 2018 Feb 13. Review.

2.

The O-specific polysaccharide lyase from the phage LKA1 tailspike reduces Pseudomonas virulence.

Olszak T, Shneider MM, Latka A, Maciejewska B, Browning C, Sycheva LV, Cornelissen A, Danis-Wlodarczyk K, Senchenkova SN, Shashkov AS, Gula G, Arabski M, Wasik S, Miroshnikov KA, Lavigne R, Leiman PG, Knirel YA, Drulis-Kawa Z.

Sci Rep. 2017 Nov 24;7(1):16302. doi: 10.1038/s41598-017-16411-4.

3.

CD1d-Restricted pathways in hepatocytes control local natural killer T cell homeostasis and hepatic inflammation.

Zeissig S, Peuker K, Iyer S, Gensollen T, Dougan SK, Olszak T, Kaser A, Blumberg RS.

Proc Natl Acad Sci U S A. 2017 Sep 26;114(39):10449-10454. doi: 10.1073/pnas.1701428114. Epub 2017 Sep 11.

4.

Phage Life Cycles Behind Bacterial Biodiversity.

Olszak T, Latka A, Roszniowski B, Valvano MA, Drulis-Kawa Z.

Curr Med Chem. 2017 Nov 24;24(36):3987-4001. doi: 10.2174/0929867324666170413100136. Review.

PMID:
28412903
5.

The temperate Burkholderia phage AP3 of the Peduovirinae shows efficient antimicrobial activity against B. cenocepacia of the IIIA lineage.

Roszniowski B, Latka A, Maciejewska B, Vandenheuvel D, Olszak T, Briers Y, Holt GS, Valvano MA, Lavigne R, Smith DL, Drulis-Kawa Z.

Appl Microbiol Biotechnol. 2017 Feb;101(3):1203-1216. doi: 10.1007/s00253-016-7924-7. Epub 2016 Oct 21.

6.

A proposed integrated approach for the preclinical evaluation of phage therapy in Pseudomonas infections.

Danis-Wlodarczyk K, Vandenheuvel D, Jang HB, Briers Y, Olszak T, Arabski M, Wasik S, Drabik M, Higgins G, Tyrrell J, Harvey BJ, Noben JP, Lavigne R, Drulis-Kawa Z.

Sci Rep. 2016 Jun 15;6:28115. doi: 10.1038/srep28115.

7.

Correction: Characterization of the Newly Isolated Lytic Bacteriophages KTN6 and KT28 and Their Efficacy against Pseudomonas aeruginosa Biofilm.

Danis-Wlodarczyk K, Olszak T, Arabski M, Wasik S, Majkowska-Skrobek G, Augustyniak D, Gula G, Briers Y, Jang HB, Vandenheuvel D, Duda KA, Lavigne R, Drulis-Kawa Z.

PLoS One. 2015 Aug 25;10(8):e0137015. doi: 10.1371/journal.pone.0137015. eCollection 2015. No abstract available.

8.

Solid Organ Transplantation in Patients with Inflammatory Bowel Diseases (IBD): Analysis of Transplantation Outcome and IBD Activity in a Large Single Center Cohort.

Schnitzler F, Friedrich M, Stallhofer J, Schönermarck U, Fischereder M, Habicht A, Karbalai N, Wolf C, Angelberger M, Olszak T, Beigel F, Tillack C, Göke B, Zachoval R, Denk G, Guba M, Rust C, Grüner N, Brand S.

PLoS One. 2015 Aug 19;10(8):e0135807. doi: 10.1371/journal.pone.0135807. eCollection 2015.

9.

Phenotypic characterization of an international Pseudomonas aeruginosa reference panel: strains of cystic fibrosis (CF) origin show less in vivo virulence than non-CF strains.

Cullen L, Weiser R, Olszak T, Maldonado RF, Moreira AS, Slachmuylders L, Brackman G, Paunova-Krasteva TS, Zarnowiec P, Czerwonka G, Reilly J, Drevinek P, Kaca W, Melter O, De Soyza A, Perry A, Winstanley C, Stoitsova SR, Lavigne R, Mahenthiralingam E, Sá-Correia I, Coenye T, Drulis-Kawa Z, Augustyniak D, Valvano MA, McClean S.

Microbiology. 2015 Oct;161(10):1961-77. doi: 10.1099/mic.0.000155. Epub 2015 Aug 6.

PMID:
26253522
10.

The NOD2 Single Nucleotide Polymorphism rs72796353 (IVS4+10 A>C) Is a Predictor for Perianal Fistulas in Patients with Crohn's Disease in the Absence of Other NOD2 Mutations.

Schnitzler F, Friedrich M, Wolf C, Stallhofer J, Angelberger M, Diegelmann J, Olszak T, Tillack C, Beigel F, Göke B, Glas J, Lohse P, Brand S.

PLoS One. 2015 Jul 6;10(7):e0116044. doi: 10.1371/journal.pone.0116044. eCollection 2015.

11.

Characterization of the Newly Isolated Lytic Bacteriophages KTN6 and KT28 and Their Efficacy against Pseudomonas aeruginosa Biofilm.

Danis-Wlodarczyk K, Olszak T, Arabski M, Wasik S, Majkowska-Skrobek G, Augustyniak D, Gula G, Briers Y, Jang HB, Vandenheuvel D, Duda KA, Lavigne R, Drulis-Kawa Z.

PLoS One. 2015 May 21;10(5):e0127603. doi: 10.1371/journal.pone.0127603. eCollection 2015. Erratum in: PLoS One. 2015;10(8):e0137015.

12.

Modern Therapeutic Approaches Against Pseudomonas aeruginosa Infections.

Dorotkiewicz-Jach A, Augustyniak D, Olszak T, Drulis-Kawa Z.

Curr Med Chem. 2015;22(14):1642-64. Review.

PMID:
25882546
13.

In vitro and in vivo antibacterial activity of environmental bacteriophages against Pseudomonas aeruginosa strains from cystic fibrosis patients.

Olszak T, Zarnowiec P, Kaca W, Danis-Wlodarczyk K, Augustyniak D, Drevinek P, de Soyza A, McClean S, Drulis-Kawa Z.

Appl Microbiol Biotechnol. 2015 Jul;99(14):6021-33. doi: 10.1007/s00253-015-6492-6. Epub 2015 Mar 12.

14.

The NOD2 p.Leu1007fsX1008 mutation (rs2066847) is a stronger predictor of the clinical course of Crohn's disease than the FOXO3A intron variant rs12212067.

Schnitzler F, Friedrich M, Wolf C, Angelberger M, Diegelmann J, Olszak T, Beigel F, Tillack C, Stallhofer J, Göke B, Glas J, Lohse P, Brand S.

PLoS One. 2014 Nov 3;9(11):e108503. doi: 10.1371/journal.pone.0108503. eCollection 2014.

15.

Protective mucosal immunity mediated by epithelial CD1d and IL-10.

Olszak T, Neves JF, Dowds CM, Baker K, Glickman J, Davidson NO, Lin CS, Jobin C, Brand S, Sotlar K, Wada K, Katayama K, Nakajima A, Mizuguchi H, Kawasaki K, Nagata K, Müller W, Snapper SB, Schreiber S, Kaser A, Zeissig S, Blumberg RS.

Nature. 2014 May 22;509(7501):497-502. doi: 10.1038/nature13150. Epub 2014 Apr 6.

16.

Involvement of the iNKT cell pathway is associated with early-onset eosinophilic esophagitis and response to allergen avoidance therapy.

Lexmond WS, Neves JF, Nurko S, Olszak T, Exley MA, Blumberg RS, Fiebiger E.

Am J Gastroenterol. 2014 May;109(5):646-57. doi: 10.1038/ajg.2014.12. Epub 2014 Feb 11.

17.

Sphingolipids from a symbiotic microbe regulate homeostasis of host intestinal natural killer T cells.

An D, Oh SF, Olszak T, Neves JF, Avci FY, Erturk-Hasdemir D, Lu X, Zeissig S, Blumberg RS, Kasper DL.

Cell. 2014 Jan 16;156(1-2):123-33. doi: 10.1016/j.cell.2013.11.042.

18.

Intestinal DMBT1 expression is modulated by Crohn's disease-associated IL23R variants and by a DMBT1 variant which influences binding of the transcription factors CREB1 and ATF-2.

Diegelmann J, Czamara D, Le Bras E, Zimmermann E, Olszak T, Bedynek A, Göke B, Franke A, Glas J, Brand S.

PLoS One. 2013 Nov 5;8(11):e77773. doi: 10.1371/journal.pone.0077773. eCollection 2013.

19.

A giant Pseudomonas phage from Poland.

Drulis-Kawa Z, Olszak T, Danis K, Majkowska-Skrobek G, Ackermann HW.

Arch Virol. 2014 Mar;159(3):567-72. doi: 10.1007/s00705-013-1844-y. Epub 2013 Sep 26.

20.

CEACAM1 on activated NK cells inhibits NKG2D-mediated cytolytic function and signaling.

Hosomi S, Chen Z, Baker K, Chen L, Huang YH, Olszak T, Zeissig S, Wang JH, Mandelboim O, Beauchemin N, Lanier LL, Blumberg RS.

Eur J Immunol. 2013 Sep;43(9):2473-83. doi: 10.1002/eji.201242676. Epub 2013 Jun 18.

21.

IRGM variants and susceptibility to inflammatory bowel disease in the German population.

Glas J, Seiderer J, Bues S, Stallhofer J, Fries C, Olszak T, Tsekeri E, Wetzke M, Beigel F, Steib C, Friedrich M, Göke B, Diegelmann J, Czamara D, Brand S.

PLoS One. 2013;8(1):e54338. doi: 10.1371/journal.pone.0054338. Epub 2013 Jan 24.

22.

Analyzing antigen recognition by Natural Killer T cells.

Zeissig S, Olszak T, Melum E, Blumberg RS.

Methods Mol Biol. 2013;960:557-572. doi: 10.1007/978-1-62703-218-6_41.

23.

PTGER4 expression-modulating polymorphisms in the 5p13.1 region predispose to Crohn's disease and affect NF-κB and XBP1 binding sites.

Glas J, Seiderer J, Czamara D, Pasciuto G, Diegelmann J, Wetzke M, Olszak T, Wolf C, Müller-Myhsok B, Balschun T, Achkar JP, Kamboh MI, Franke A, Duerr RH, Brand S.

PLoS One. 2012;7(12):e52873. doi: 10.1371/journal.pone.0052873. Epub 2012 Dec 27.

24.

Analysis of IL12B gene variants in inflammatory bowel disease.

Glas J, Seiderer J, Wagner J, Olszak T, Fries C, Tillack C, Friedrich M, Beigel F, Stallhofer J, Steib C, Wetzke M, Göke B, Ochsenkühn T, Diegelmann J, Czamara D, Brand S.

PLoS One. 2012;7(3):e34349. doi: 10.1371/journal.pone.0034349. Epub 2012 Mar 30.

25.

PTPN2 gene variants are associated with susceptibility to both Crohn's disease and ulcerative colitis supporting a common genetic disease background.

Glas J, Wagner J, Seiderer J, Olszak T, Wetzke M, Beigel F, Tillack C, Stallhofer J, Friedrich M, Steib C, Göke B, Ochsenkühn T, Karbalai N, Diegelmann J, Czamara D, Brand S.

PLoS One. 2012;7(3):e33682. doi: 10.1371/journal.pone.0033682. Epub 2012 Mar 21.

26.

Microbial exposure during early life has persistent effects on natural killer T cell function.

Olszak T, An D, Zeissig S, Vera MP, Richter J, Franke A, Glickman JN, Siebert R, Baron RM, Kasper DL, Blumberg RS.

Science. 2012 Apr 27;336(6080):489-93. doi: 10.1126/science.1219328. Epub 2012 Mar 22.

27.

The role of osteopontin (OPN/SPP1) haplotypes in the susceptibility to Crohn's disease.

Glas J, Seiderer J, Bayrle C, Wetzke M, Fries C, Tillack C, Olszak T, Beigel F, Steib C, Friedrich M, Diegelmann J, Czamara D, Brand S.

PLoS One. 2011;6(12):e29309. doi: 10.1371/journal.pone.0029309. Epub 2011 Dec 29.

28.

CEACAM1 dampens antitumor immunity by down-regulating NKG2D ligand expression on tumor cells.

Chen Z, Chen L, Baker K, Olszak T, Zeissig S, Huang YH, Kuo TT, Mandelboim O, Beauchemin N, Lanier LL, Blumberg RS.

J Exp Med. 2011 Dec 19;208(13):2633-40. doi: 10.1084/jem.20102575. Epub 2011 Dec 5.

30.

Cyclooxygenase-2 deficiency leads to intestinal barrier dysfunction and increased mortality during polymicrobial sepsis.

Fredenburgh LE, Velandia MM, Ma J, Olszak T, Cernadas M, Englert JA, Chung SW, Liu X, Begay C, Padera RF, Blumberg RS, Walsh SR, Baron RM, Perrella MA.

J Immunol. 2011 Nov 15;187(10):5255-67. doi: 10.4049/jimmunol.1101186. Epub 2011 Oct 3.

31.

Pregnane X receptor (PXR/NR1I2) gene haplotypes modulate susceptibility to inflammatory bowel disease.

Glas J, Seiderer J, Fischer D, Tengler B, Pfennig S, Wetzke M, Beigel F, Olszak T, Weidinger M, Göke B, Ochsenkühn T, Folwaczny M, Müller-Myhsok B, Diegelmann J, Czamara D, Brand S.

Inflamm Bowel Dis. 2011 Sep;17(9):1917-24. doi: 10.1002/ibd.21562. Epub 2010 Dec 3.

PMID:
21830270
32.

CEACAM6 gene variants in inflammatory bowel disease.

Glas J, Seiderer J, Fries C, Tillack C, Pfennig S, Weidinger M, Beigel F, Olszak T, Lass U, Göke B, Ochsenkühn T, Wolf C, Lohse P, Müller-Myhsok B, Diegelmann J, Czamara D, Brand S.

PLoS One. 2011 Apr 29;6(4):e19319. doi: 10.1371/journal.pone.0019319.

33.

The NOD2 single nucleotide polymorphisms rs2066843 and rs2076756 are novel and common Crohn's disease susceptibility gene variants.

Glas J, Seiderer J, Tillack C, Pfennig S, Beigel F, Jürgens M, Olszak T, Laubender RP, Weidinger M, Müller-Myhsok B, Göke B, Ochsenkühn T, Lohse P, Diegelmann J, Czamara D, Brand S.

PLoS One. 2010 Dec 30;5(12):e14466. doi: 10.1371/journal.pone.0014466.

34.

IL-22-mediated liver cell regeneration is abrogated by SOCS-1/3 overexpression in vitro.

Brand S, Dambacher J, Beigel F, Zitzmann K, Heeg MH, Weiss TS, Prüfer T, Olszak T, Steib CJ, Storr M, Göke B, Diepolder H, Bilzer M, Thasler WE, Auernhammer CJ.

Am J Physiol Gastrointest Liver Physiol. 2007 Apr;292(4):G1019-28. Epub 2007 Jan 4.

35.

IL-22 is increased in active Crohn's disease and promotes proinflammatory gene expression and intestinal epithelial cell migration.

Brand S, Beigel F, Olszak T, Zitzmann K, Eichhorst ST, Otte JM, Diepolder H, Marquardt A, Jagla W, Popp A, Leclair S, Herrmann K, Seiderer J, Ochsenkühn T, Göke B, Auernhammer CJ, Dambacher J.

Am J Physiol Gastrointest Liver Physiol. 2006 Apr;290(4):G827-38.

36.

Cell differentiation dependent expressed CCR6 mediates ERK-1/2, SAPK/JNK, and Akt signaling resulting in proliferation and migration of colorectal cancer cells.

Brand S, Olszak T, Beigel F, Diebold J, Otte JM, Eichhorst ST, Göke B, Dambacher J.

J Cell Biochem. 2006 Mar 1;97(4):709-23.

PMID:
16215992
37.

CXCR4 and CXCL12 are inversely expressed in colorectal cancer cells and modulate cancer cell migration, invasion and MMP-9 activation.

Brand S, Dambacher J, Beigel F, Olszak T, Diebold J, Otte JM, Göke B, Eichhorst ST.

Exp Cell Res. 2005 Oct 15;310(1):117-30.

PMID:
16125170
38.

IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression.

Brand S, Beigel F, Olszak T, Zitzmann K, Eichhorst ST, Otte JM, Diebold J, Diepolder H, Adler B, Auernhammer CJ, Göke B, Dambacher J.

Am J Physiol Gastrointest Liver Physiol. 2005 Nov;289(5):G960-8. Epub 2005 Jul 28.

39.

SOCS-1 inhibits expression of the antiviral proteins 2',5'-OAS and MxA induced by the novel interferon-lambdas IL-28A and IL-29.

Brand S, Zitzmann K, Dambacher J, Beigel F, Olszak T, Vlotides G, Eichhorst ST, Göke B, Diepolder H, Auernhammer CJ.

Biochem Biophys Res Commun. 2005 Jun 3;331(2):543-8.

PMID:
15850793
40.

1,3-thiazolidine derivatives from regioselective [2+3]-cycloadditions of azomethine ylides with thioketones.

Domagała M, Linden A, Olszak TA, Mlostoń G, Heimgartner H.

Acta Crystallogr C. 2003 May;59(Pt 5):o250-3. Epub 2003 Apr 18.

PMID:
12743406
41.

trans-Diaquatetrakis(3,5-dimethylpyrazole-N2)nickel(II) dichloride.

Malecka M, Rybarczyk-Pirek A, Olszak TA, Malinowska K, Ochocki J.

Acta Crystallogr C. 2001 May;57(Pt 5):513-4. Epub 2001 May 15.

PMID:
11353232
42.

X-ray structure investigations of potential beta-blockers. II.6,7-Dimethoxy-1-phenyl-1,2,3,4-tetrahydroisoquinoline.

Olszak TA, Stepień A, Grabowski MJ, Brzezińska E.

Acta Crystallogr C. 1996 Apr 15;52 ( Pt 4):1038-40.

PMID:
8624238
43.

Structure-activity relationship of new 10-13 membered oxygen-nitrogen heterocyclic systems containing two aromatic rings.

Walczyński K, Glinka R, Stepień A, Olszak T, Sabatino P.

Pharmazie. 1992 Jun;47(6):409-11.

PMID:
1357679

Supplemental Content

Loading ...
Support Center